Immunome IMNM
NASDAQ IMNM
$26.75 -0.41 (-1.51%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunome (IMNM) EBT Growth (3y) (2022 - 2026)

Analysis

Immunome (IMNM) EBT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.22%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 12.16%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 103.79%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 24.03%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 41.79%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 38.36%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -38.56%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 64.03%
10 Immunome 3.03 Bn 2.51 Bn - -138.31%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -138.31%
Mar 31, 2026 -136.75%
Dec 31, 2025 -110.72%
Sep 30, 2025 -91.72%
Jun 30, 2025 -73.33%
Mar 31, 2025 -56.46%
Dec 31, 2024 -119.51%
Sep 30, 2024 -87.02%
Jun 30, 2024 -91.02%
Mar 31, 2024 -223.80%
Dec 31, 2023 -185.37%
Sep 30, 2023 17.92%
Jun 30, 2023 -28.59%
Mar 31, 2023 -18.97%
Dec 31, 2022 -38.64%
Sep 30, 2022 -46.09%